FDA approves new targeted therapy for relapsed or refractory acute myeloid leukemia (AML).
On August 1, 2017, FDA approved Idhifa (enasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) and a distinct gene mutation. The drug is approved for use with companion diagnostic RealTime IDH2 Assay, which is used to detect mutations in the IDH2 gene in AML patients.
“Idhifa is a targeted therapy that fills an unmet need for patients with relapsed or refractory AML who have an IDH2 mutation,” stated Richard Pazdur, MD, director of the FDA’s Oncology Center of Excellence and acting director of the Office of Hematology and Oncology Products in FDA’s Center for Drug Evaluation and Research, in a press release. “The use of Idhifa was associated with a complete remission in some patients and a reduction in the need for both red cell and platelet transfusions.”
AML is a fast-growing bone marrow cancer that results in an abnormal increase of white blood cells in the bone marrow and blood stream. Known as an isocitrate dehydrogenase-2 inhibitor, the drug is designed to inhibit cell growth by blocking the responsible enzymes. Patients that qualify for the treatment are those who possess the IDH2 mutation in bone marrow or blood samples by the accompanying companion diagnostic.
FDA granted approval of the drug to Celgene Corporation, a global biopharmaceutical company aimed at developing treatments for cancer and other inflammatory disease. The companion diagnostic is approved for Abbott Laboratories.
Sources: FDA
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.